Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07186179 · ClinicalTrials.gov registry record

Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)

A clinical trial of Diamond-Blackfan Anemia, sponsored by Northwell Health.

Recruiting
Registry status
10
Enrollment target
1
Study location

NCT07186179: Recruiting study of Diamond-Blackfan Anemia, sponsored by Northwell Health.

NCT07186179 is a study of Diamond-Blackfan Anemia that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 10 participants, below the 708-participant average among 11 other Diamond-Blackfan Anemia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07186179, a study of Diamond-Blackfan Anemia, is actively recruiting participants, sponsored by Northwell Health.

RECRUITING
Registry status
10 participants
Enrollment target
1
Study location

Study Summary

Gene therapy is a new possible treatment for the anemia of DBAS. Gene therapy will soon be available for patients with RPS19-mutated DBAS. This involves inserting the corrected RPS19 gene into the cells, leading to correction of the anemia. The application of gene therapy requires sufficient numbers of stem cells on which the correction can be performed. Stem cells must be mobilized (stimulated to move) from the bone marrow to the peripheral blood and then collected (also called 'harvested'). It is not known if patients with DBAS can mobilize enough stem cells into the peripheral blood to allow for the harvesting of sufficient numbers to permit genetic manipulation. It is important to demonstrate the ability to harvest an adequate number of stem cells before gene therapy can be tried in patients with DBAS. The purpose of this study is to determine if mobilization of stem cells from the bone marrow in patients with DBAS is enough to obtain the numbers of peripheral blood stem cells necessary for effective gene therapy. An actual harvest will not be done.

Primary Outcome

This study will analyze the number of participants that successfully achieve 5-30 CD34+ cells/µL peripheral blood during the study period.

Conditions Studied

Interventions

  • DRUG Mobilization Regimen

Study Locations (1)

New York

  • Cohen Children's Medical Center - New Hyde Park

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-10-01
Est. Completion 2027-04-01
Northwell Health

370 total trials

What NCT07186179 shows while recruiting

NCT07186179 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 708-participant average among 11 other Diamond-Blackfan Anemia trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Diamond-Blackfan Anemia appearing as the primary indexed condition, and to 1 intervention - of which Mobilization Regimen is the first listed.

NCT07186179 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07186179 about?

NCT07186179 is a clinical study titled "Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)". Gene therapy is a new possible treatment for the anemia of DBAS. Gene therapy will soon be available for patients with RPS19-mutated DBAS. This involves inserting the corrected RPS19 gene into the cells, leading to correction of the anemia. The application of gene therapy requires sufficient numbers...

What is the current status of trial NCT07186179?

This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2025-10-01. Estimated completion is 2027-04-01.

What conditions does trial NCT07186179 study?

This clinical trial studies the following conditions: Diamond-Blackfan Anemia.

What interventions are being tested in trial NCT07186179?

The interventions under investigation include: Mobilization Regimen (DRUG).

Who is sponsoring clinical trial NCT07186179?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07186179 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diamond-Blackfan Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07186179's enrollment target sits among peer trials

10 10th of 11 higher than 2 of 11 other Diamond-Blackfan Anemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diamond-Blackfan Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07186179, the US trial registry maintained by the National Library of Medicine. NCT07186179 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.